Sanofi ADR (SNY)vsMolson Coors Brewing Co Class B (TAP)
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
TAP
Molson Coors Brewing Co Class B
$41.27
+0.27%
CONSUMER DEFENSIVE · Cap: $8.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 319% more annual revenue ($46.72B vs $11.14B). SNY leads profitability with a 16.7% profit margin vs -19.2%. TAP appears more attractively valued with a PEG of 4.11. SNY earns a higher WallStSmart Score of 49/100 (D+).
SNY
Hold49
out of 100
Grade: D+
TAP
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Intrinsic value data unavailable for TAP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Expensive relative to growth rate
ROE of -18.2% — below average capital efficiency
Revenue declined 2.7%
Earnings declined 12.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bull Case : TAP
The strongest argument for TAP centers on Price/Book.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Bear Case : TAP
The primary concerns for TAP are PEG Ratio, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
SNY profiles as a mature stock while TAP is a turnaround play — different risk/reward profiles.
TAP carries more volatility with a beta of 0.45 — expect wider price swings.
SNY is growing revenue faster at 6.9% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (49/100 vs 44/100), backed by strong 16.7% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Molson Coors Brewing Co Class B
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?